LKFT
NASDAQLakefront Biotherapeutics
Lakefront Biotherapeutics (LKFT) is a Biotechnology: Pharmaceutical Preparations company listed on NASDAQ. In the last 30 days Quantisnow tracked 4 wire items for LKFT, including 2 SEC filings, 1 leadership change and 1 earnings update. The most recent was published Nov 4, 2026.
LKFT rankings
Financial highlights
Full financials- Revenue, FY2025
- €1.11B
- Revenue growth
- +303.5%
- Net income, FY2025
- €320.88M
- Net margin
- 28.9%
- Free cash flow, FY2025
- -€271.16M
- Cash
- €87.87M
For fiscal 2025 (ended Dec 31, 2025), from SEC filings. Not investment advice.
News · 26 weeks4+100%
2026-05-172026-11-08
Mix490d
- SEC Filings2(50%)
- Leadership1(25%)
- Earnings1(25%)
Activity · 52 weeks42 active days
Tap a day to see what happenedEarningsInsiderAnalystFilings and news
Latest news
4 items- SECSEC Form 6-K filed by Lakefront Biotherapeutics6-K - Lakefront Biotherapeutics NV (0001421876) (Filer)
- PRLakefront Biotherapeutics Announces Poster Presentation at the 2026 American Society of Hematology MeetingGamgertamig data from ongoing Phase 1b studies suggest potential to retain remission after B cell reconstitution, maintained in the absence of background therapy for autoimmune cytopenias, consistent with an "immune reset" Lakefront to host investor conference call on Monday, December 14 at 8 AM ET Mechelen, Belgium; November 4, 2026, 15.01 CET – Lakefront Biotherapeutics NV ((Euronext &, NASDAQ:LKFT) today announced the acceptance of a poster presentation at the 2026 American Society of Hematology (ASH) Annual Meeting taking place on December 12-15 in New Orleans, LA. "Prior to acquiring Ouro together with Gilead, we recognized gamgertamig’s potential to change clinical practice for pat
- SECSEC Form 6-K filed by Lakefront Biotherapeutics6-K - Lakefront Biotherapeutics NV (0001421876) (Filer)
- PRLakefront Biotherapeutics Welcomes Dr. Mehdi Shahidi to its Board of DirectorsDr. Shahidi brings extensive drug development experience, regulatory success, and transformative operational expertise to the Board Mechelen, Belgium; November 2, 2026, 22.01 CET; Lakefront Biotherapeutics NV ((Euronext &, NASDAQ:LKFT) today announced the appointment by way of co-optation of Dr. Mehdi Shahidi as Non-Executive Independent Director to its Board of Directors, effective November 2, 2026. He replaces Dr. Paulo Fontoura, who resigned from the Board in July 2026 following his appointment as the Global Head of R&D at Sanofi SA. "We are thrilled to welcome Mehdi to the Board. I’m confident his extensive experience in drug development, history of regulatory success, and track record
LKFT FAQ
10 questionsWhat does Lakefront Biotherapeutics do?
Lakefront Biotherapeutics is a biotechnology company dedicated to building a differentiated pipeline of medicines for patients with serious diseases in areas of high unmet need. The Company has established a clinical-stage portfolio in immunology and inflammation, anchored by gamgertamig, a potential first-in-class and best-in-class BCMAxCD3 T-cell engager for autoimmune diseases. Backed by deep deal-making expertise, operational flexibility, and a strong capital position, Lakefront identifies, acquires, and advances high-quality assets with clear potential to deliver meaningful patient...What is the latest news on LKFT?
In the last 30 days Quantisnow tracked 4 wire items for LKFT: 2 SEC filings, 1 leadership change and 1 earnings update. The most recent was published on November 4, 2026.What is LKFT revenue?
Lakefront Biotherapeutics (LKFT) reported €1.11B of revenue for fiscal 2025 (ended Dec 31, 2025). That is up 303.5% from the year before.Is LKFT profitable?
Yes. Lakefront Biotherapeutics earned €320.88M in net income for fiscal 2025 (ended Dec 31, 2025), a net margin of 28.9%.How much cash and debt does LKFT have?
Lakefront Biotherapeutics reported €87.87M in cash and cash equivalents on its most recent balance sheet in SEC filings.Where does LKFT stock trade?
Lakefront Biotherapeutics (LKFT) is listed on NASDAQ.What sector and industry is LKFT in?
Lakefront Biotherapeutics operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Lakefront Biotherapeutics go public?
Lakefront Biotherapeutics (LKFT) completed its IPO in 2015.What companies are similar to LKFT?
Notable peers in the same industry include MRK (Merck & Company Inc.), JNJ (Johnson & Johnson), ABT (Abbott Laboratories), ABBV (AbbVie Inc.), NVS (Novartis AG). Compare LKFT side-by-side with any of them on Quantisnow.How can I track LKFT on Quantisnow?
Quantisnow aggregates Lakefront Biotherapeutics's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow LKFT to receive live email and push alerts on every new disclosure.